<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364648</url>
  </required_header>
  <id_info>
    <org_study_id>680076-2</org_study_id>
    <nct_id>NCT02364648</nct_id>
  </id_info>
  <brief_title>Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease</brief_title>
  <official_title>Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Delaware</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Delaware</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of mitochondria derived oxidative stress
      on vascular function in patients with moderate to severe Chronic Kidney Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Kidney Disease (CKD) patients are at increased risk of cardiovascular disease.
      Endothelial dysfunction, characterized by a reduced bioavailability in nitric oxide, is an
      independent predictor of cardiovascular disease in CKD. Increased oxidative stress is a
      potential cause of endothelial dysfunction in this patient cohort. This study investigates
      the role that mitochondrial derived oxidative stress plays in CKD related vascular
      dysfunction. In a controlled, double blinded trial, Stage 3-5 CKD patients will be randomly
      assigned to receive a 4 week daily dose of a mitochondria targeted antioxidant (MitoQ) or a
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular Function, assessed by laser Doppler flowmetry coupled with microdialysis</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>Nitric oxide mediated cutaneous microvascular dilatory response to local heating assessed by laser Doppler flowmetry coupled with microdialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conduit artery endothelial dependent dilation, assessed by duplex ultrasound</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>Brachial artery flow mediated dilation assessed by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondria derived superoxide, assessed by electron paramagnetic resonance spectroscopy</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>Plasma mitochondria superoxide assessed by electron paramagnetic resonance spectroscopy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Endothelial cell NADPH oxidase expression</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>NADPH oxidase expression in human endothelial cll expression</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial Stiffness, assessed by central blood pressure, augmentation index and carotid artery to femoral artery pulse wave velocity</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>Central blood pressure, augmentation index and carotid artery to femoral artery pulse wave velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ambulatory Blood Pressure</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>2h hour continuous ambulatory blood pressure monitoring</description>
  </other_outcome>
  <other_outcome>
    <measure>Habitual Physical Activity, assessed by accelerometry</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>Daily habitual physical activity assessed by accelerometry</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>MitoQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week 20mg oral daily dose of MitoQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 week 20mg oral daily placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MitoQ</intervention_name>
    <description>Mitochondria targeted antioxidant</description>
    <arm_group_label>MitoQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 3 - 5 Chronic Kidney Disease

        Exclusion Criteria:

          -  History of cardiovascular disease;

          -  Current pregnancy;

          -  Uncontrolled hypertension;

          -  Uncontrolled hyperlipidemia;

          -  Current hormone replacement therapy;

          -  Current use of tobacco products;

          -  Elevated liver enzymes;

          -  Current autoimmune disease;

          -  Daily use of of antioxidants &gt;300mg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle L Kirkman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Delaware</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David G Edwards, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Delaware</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle L Kirkman, PhD</last_name>
    <phone>302 831 4659</phone>
    <email>dkirkman@udel.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David G Edwards, PhD</last_name>
    <email>dge@udel.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Kinesiology and Applied Physiology, University of Delaware</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Edwards, PhD</last_name>
      <email>dge@udel.edu</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Kirkman, PhD</last_name>
      <email>dkirkman@udel.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Danielle Kirkman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Edwards, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Delaware</investigator_affiliation>
    <investigator_full_name>David Edwards</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Endothelium, vascular</keyword>
  <keyword>MitoQ</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Chronic Renal Insufficiency</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

